loss) per diluted share for the 2012 and 2011 reporting periods, please see Table 1 at the end of this press release. AMRI Chairman, President and CEO Thomas E. D'Ambra said, "We are pleased to report fourth quarter and full year results for 2012, which reflect operating improvements largely driven by the record performance in our Large Scale Manufacturing business. In addition, a number of actions taken in prior periods are demonstrating a positive impact on our bottom line. Our overall performance for fiscal year 2012 demonstrates the consistent and positive direction our company is moving as we continue to position and integrate our global facilities and high quality services. Although discovery and early development demand continues to be soft relative to prior periods, we have also delivered progress and entered into new relationships that hold promise for future growth. We are building key long-term relationships with customers that will benefit us in 2013 and beyond. Led by the AMRI SMARTSOURCING™ strategy implemented in the first quarter of 2012, AMRI is well positioned to maintain positive momentum into 2013 and, most importantly, support and help our customers discover, develop and bring to market the exciting drugs of today and tomorrow."
"As we enter 2013 and look beyond as well, we are optimistic about our ability to lead the industry to new business models and relationships, and we are encouraged by the decisions we made throughout 2012 to set us on the right path to continued profitability," added Dr. D'Ambra.
Liquidity and Capital ResourcesAt December 31, 2012, AMRI had cash, cash equivalents, and restricted cash of $28.5 million, compared to $20.2 million at December 31, 2011. These amounts in 2012 include $5.2 million of restricted cash, $5.0 million of which was pledged to collateralize the company's term loan and line of credit.
Total debt at December 31, 2012 was $8.0 million compared to $5.8 million at December 31, 20Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 Related biology technology :1
. Quantum Materials Corporation Announces Non-Heavy Metal (Cadmium-Free) Tetrapod Quantum Dots2
. The In View Series Announces Plans for a New Series on 3D-Printing3
. Elsevier Announces the Launch of a New Journal: Journal of Forensic Radiology and Imaging4
. The In View series hosted by Larry King Announces plans for a series on Autoimmune Diseases5
. Murray Test Prep Announces the Launch of their Online Tutoring Services6
. EastBridge Investment Group Announces Completion of its Merger with Cellular Biomedicine Group - Shareholder Conference Call to be held February 8th7
. MiMedx Group, Inc. Announces Release Date for 2012 Fourth Quarter Results8
. China Cord Blood Corporation Announces Completion of Corporate Structure Consolidation9
. DNA Genotek Inc. Announces $10,000 GenoFIND™ Genomic Services Award10
. Spectrum Announces bioWorld Distribution Agreement11
. Life Technologies Announces Fourth Quarter and Fiscal 2012 Results